ALLO: Allogene Therapeutics, Inc. Stock

by  •  • Comments Off on ALLO: Allogene Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 250.94
Enterprise Value ($M) 175.72
Book Value ($M) 422.18
Book Value / Share 1.94
Price / Book 0.59
NCAV ($M) 176.85
NCAV / Share 0.81
Price / NCAV 1.42

Profitability (mra)
Return on Invested Capital (ROIC) -0.50
Return on Assets (ROA) -0.44
Return on Equity (ROE) -0.56

Liquidity (mrq)
Quick Ratio 8.54
Current Ratio 8.54

Balance Sheet (mrq) ($M)
Current Assets 303.39
Assets 548.71
Liabilities 126.53
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.02
Operating Income -257.48
Net Income -257.59
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations -200.30
Cash from Investing 75.69
Cash from Financing 116.67

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
3 days ago 13G/A Belldegrun Arie 5.70 1.21
3 days ago 13G/A Chang David D 5.00 1.27
04-17 13G/A BlackRock, Inc. 5.30 -35.58
03-07 13G/A Fmr Llc 4.90 -56.98
02-14 13G Lynx1 Capital Management LP 5.20
11-12 13G/A Vanguard Group Inc 3.98 0.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2025-03-13 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 ☐ TRANSITION REPORT PURSUA
2024-11-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REP
2024-08-07 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT P
2024-05-13 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-05-09 797,737 2,163,303 36.88
2025-05-08 2,088,659 7,363,958 28.36
2025-05-07 3,930,083 6,330,641 62.08
2025-05-06 1,985,846 5,568,774 35.66

(click for more detail)

Similar Companies
ALEC – Alector, Inc. ALKS – Alkermes plc
ALLK – Allakos Inc. ALNY – Alnylam Pharmaceuticals, Inc.
ALXO – ALX Oncology Holdings Inc.


Financial data and stock pages provided by
Fintel.io